TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Noxopharm Ltd. ( (AU:NOX) ) has provided an announcement.
Noxopharm Limited announced that all resolutions were passed at its Annual General Meeting, with significant support for the adoption of the Remuneration Report. The company’s Sofra technology platform, which targets inflammatory and autoimmune diseases, holds potential for significant market impact, given the projected growth in the autoimmune disease therapeutics and immuno-oncology markets.
More about Noxopharm Ltd.
Noxopharm Limited is a clinical-stage Australian biotech company focused on discovering and developing novel treatments for cancer and inflammation. The company utilizes its proprietary Sofra and Chroma technology platforms to enhance mRNA medicines and develop drugs targeting inflammation, autoimmunity, and oncology.
Average Trading Volume: 109,444
Technical Sentiment Signal: Sell
Current Market Cap: A$26.3M
For an in-depth examination of NOX stock, go to TipRanks’ Overview page.